From mixed topline results from a Phase 3 trial of lead candidate to the potential need to fund and conduct another trial prior to seeking regulatory approval, Cary Claiborne has been faced with multiple challenges since becoming CEO of Adial Pharma in August.

In working on this month’s cover story, which features Imagine Pharma, a preclinical stage biotech based in Pittsburgh, it was hard not to get swept up in the enthusiasm and promise of the company’s autologous cell therapy treatment for Type 1 diabetes (T1D).

From the looks of its modest open floor plan lab in Pittsburgh’s uptown, it might not be obvious to the casual observer that Imagine Pharma and its nine-person full-time workforce are developing multiple pharmaceutical products across three distinct platforms.

Karuna Therapeutics’ late-stage drug for schizophrenia, if approved, could fund the company’s pipeline of next generation psychiatric drugs discovered through a modular constellation of CRO partners.

Ninety-four percent of PhRMA’s member companies responding to a survey published in December 2020 reported the existence of “employee resource groups” within their organizations, defined as an “employer recognized group of employees who share the concerns of a common race, gender, national origin, or sexual orientation.”

Can Bayer’s “arm’s-length model” for acquired companies help turn the century-and-a-half year-old Big Pharma into a leader in gene and cell therapy, and a top 10 player in oncology?

Alnylam CEO Yvonne Greenstreet talks about what’s next for the company, including a transition into larger therapeutic areas and patient populations, and describes her own journey to the CEO role.  

Representation at the top of any profession, whether jurisprudence or biotechnology, works as an accelerator for younger generations to follow.

KemPharm’s experience in reworking product NDAs following FDA Complete Response Letters has created a unique capability within the company, and helped it move to acquire a potentially valuable asset from distressed biopharma Orphazyme.